Third, it is crucial to distinguish between lifelong genetic proxies and acute pharmacological interventions
In the NEJM 2023 phase 2 trial, the highest-dose group achieved approximately 24% mean body weight reduction at 48 weeks, exceeding results reported for both semaglutide and tirzepatide in their own trials
Mistake 2: eating or drinking too soon The 30-minute fasting window after dosing exists for a reason
Retatrutide is a research peptide that requires proper reconstitution before use
DOI: 10.1136/bmj-2025-085304 Funding: National Institute of Health and Care Research (NIHR) Oxford Biomedical Research Centre Never miss a breakthrough: Join the SciTechDaily newsletter
Often referred to as GLP-3 (RT) because of its triple-action approach, Retatrutide works differently than traditional GLP-1 therapies by interacting with three key metabolic pathways involved in appetite regulation, energy balance, and metabolism